Summary & Overview
HCPCS J9100: Injection, Cytarabine 100 mg
HCPCS Level II code J9100 denotes a 100 mg injection of cytarabine, a core chemotherapeutic agent used in treatment of various hematologic cancers. Nationally, accurate coding of cytarabine administrations is important for clinical documentation, medication safety, and consistent reimbursement across outpatient, office-based, and infusion settings. This code is used whenever a 100 mg unit of cytarabine is administered and billed as a drug supply line item.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The discussion covers payer coverage patterns, typical sites of service where J9100 is billed, and common clinical contexts for cytarabine use.
Readers will learn: standardized description and clinical context for J9100; what service lines and sites commonly bill this HCPCS Level II code; how major payers approach coverage and billing for chemotherapy drug units; and practical benchmarks and policy considerations affecting documentation and claim submission. Data elements not provided in the input (for example, specific payer policies, detailed fee schedules, or associated ICD-10 diagnoses) are noted as unavailable in the input.
Billing Code Overview
HCPCS Level II code J9100 describes an injection of cytarabine, 100 mg. This code represents a single administration unit for the chemotherapeutic agent cytarabine, commonly used in oncology regimens for hematologic malignancies.
Service Type: Medication administration (chemotherapy drug)
Typical Site of Service: Hospital outpatient department, physician office, or infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acute myeloid leukemia (AML) or another hematologic malignancy requiring cytotoxic intramuscular or subcutaneous chemotherapy. The patient presents to an oncology infusion clinic or hospital oncology unit for administration of J9100 (cytarabine, 100 mg). The clinical workflow includes: outpatient or inpatient order entry by the oncologist, verification of diagnosis and baseline labs (CBC with differential, metabolic panel), pharmacy preparation of a preservative-free cytarabine syringe or vial dosed per body surface area, and administration by an oncology nurse via subcutaneous or intramuscular injection or as part of a compounded regimen. Vital signs and chemotherapy consent are documented prior to administration. Post‑administration monitoring focuses on immediate injection‑site reaction, myelosuppression surveillance, and scheduling of follow‑up labs and subsequent chemotherapy cycles. Billing is processed using J9100 with applicable modifiers to indicate circumstances such as distinct procedural service, outpatient hospital, or provider status, and payer-specific requirements are followed for prior authorization and drug reimbursement.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Use when part of the prepared cytarabine dose is discarded and documentation supports wastage billing for single‑use vial. |